Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 184

1.

Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients.

Sanai N, Li J, Boerner J, Stark K, Wu J, Kim S, Derogatis A, Mehta S, Dhruv HD, Heilbrun LK, Berens ME, LoRusso PM.

Clin Cancer Res. 2018 May 24. doi: 10.1158/1078-0432.CCR-17-3348. [Epub ahead of print]

PMID:
29798906
3.

A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma.

Goncalves PH, Heilbrun LK, Barrett MT, Kummar S, Hansen AR, Siu LL, Piekarz RL, Sukari AW, Chao J, Pilat MJ, Smith DW, Casetta L, Boerner SA, Chen A, Lenkiewicz E, Malasi S, LoRusso PM.

Oncotarget. 2017 May 16;8(20):32918-32929. doi: 10.18632/oncotarget.16464.

4.

A Pilot Trial Evaluating Zoledronic Acid Induced Changes in [18F]FMAU-Positron Emission Tomography Imaging of Bone Metastases in Prostate Cancer.

Vaishampayan UN, Tehrani OS, Lawhorn-Crews JM, Heilbrun LK, Dobson K, Smith D, Dickow B, Shields AF.

Mol Imaging Biol. 2017 Dec;19(6):810-816. doi: 10.1007/s11307-017-1057-y.

PMID:
28289967
5.

Phase II Trial of Dose-dense Pemetrexed, Gemcitabine, and Bevacizumab in Patients With Advanced, Non-Small-cell Lung Cancer.

Schneider BJ, Kalemkerian GP, Gadgeel SM, Valdivieso M, Hackstock DM, Chen W, Heilbrun LK, Ruckdeschel JC, Wozniak AJ.

Clin Lung Cancer. 2017 May;18(3):299-302. doi: 10.1016/j.cllc.2016.11.019. Epub 2016 Dec 2.

PMID:
28063799
6.

Outcomes of nonsurgical management of locally advanced carcinomas of the sinonasal cavity.

Chopra S, Kamdar DP, Cohen DS, Heilbrun LK, Smith D, Kim H, Lin HS, Jacobs JR, Yoo G.

Laryngoscope. 2017 Apr;127(4):855-861. doi: 10.1002/lary.26228. Epub 2016 Nov 15.

7.

The influence of PSA autoantibodies in prostate cancer patients: a prospective clinical study-II.

Nakajima K, Heilbrun LK, Smith D, Hogan V, Raz A, Heath E.

Oncotarget. 2017 Mar 14;8(11):17643-17650. doi: 10.18632/oncotarget.12620.

8.

Positive associations between galectin-3 and PSA levels in prostate cancer patients: a prospective clinical study-I.

Nakajima K, Heilbrun LK, Hogan V, Smith D, Heath E, Raz A.

Oncotarget. 2016 Dec 13;7(50):82266-82272. doi: 10.18632/oncotarget.12619.

9.

Anti-androgenic activity of absorption-enhanced 3, 3'-diindolylmethane in prostatectomy patients.

Hwang C, Sethi S, Heilbrun LK, Gupta NS, Chitale DA, Sakr WA, Menon M, Peabody JO, Smith DW, Sarkar FH, Heath EI.

Am J Transl Res. 2016 Jan 15;8(1):166-76. eCollection 2016.

10.

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors.

LoRusso PM, Li J, Burger A, Heilbrun LK, Sausville EA, Boerner SA, Smith D, Pilat MJ, Zhang J, Tolaney SM, Cleary JM, Chen AP, Rubinstein L, Boerner JL, Bowditch A, Cai D, Bell T, Wolanski A, Marrero AM, Zhang Y, Ji J, Ferry-Galow K, Kinders RJ, Parchment RE, Shapiro GI.

Clin Cancer Res. 2016 Jul 1;22(13):3227-37. doi: 10.1158/1078-0432.CCR-15-0652. Epub 2016 Feb 3.

11.

A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study.

Thakur MK, Heilbrun LK, Sheng S, Stein M, Liu G, Antonarakis ES, Vaishampayan U, Dzinic SH, Li X, Freeman S, Smith D, Heath EI.

Invest New Drugs. 2016 Feb;34(1):112-8. doi: 10.1007/s10637-015-0307-6. Epub 2015 Nov 18.

PMID:
26581400
12.

PET scans as a predictive marker of survival in advanced colorectal cancer.

Choi M, Kollepara SL, Heilbrun LK, Smith D, Shields AF, Philip PA.

Clin Colorectal Cancer. 2015 Mar;14(1):35-40. doi: 10.1016/j.clcc.2014.10.001. Epub 2014 Oct 23.

13.

Reducing prostate cancer racial disparity: evidence for aggressive early prostate cancer PSA testing of African American men.

Powell IJ, Vigneau FD, Bock CH, Ruterbusch J, Heilbrun LK.

Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1505-11. doi: 10.1158/1055-9965.EPI-13-1328. Epub 2014 May 6.

14.

Soft-tissue cryoablation in diffuse locations: feasibility and intermediate term outcomes.

Littrup PJ, Bang HJ, Currier BP, Goodrich DJ, Aoun HD, Heilbrun LK, Adam BA.

J Vasc Interv Radiol. 2013 Dec;24(12):1817-25. doi: 10.1016/j.jvir.2013.06.025. Epub 2013 Sep 20.

15.

Transcriptional regulation of CXCR4 in prostate cancer: significance of TMPRSS2-ERG fusions.

Singareddy R, Semaan L, Conley-Lacomb MK, St John J, Powell K, Iyer M, Smith D, Heilbrun LK, Shi D, Sakr W, Cher ML, Chinni SR.

Mol Cancer Res. 2013 Nov;11(11):1349-61. doi: 10.1158/1541-7786.MCR-12-0705. Epub 2013 Aug 5.

16.

Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer.

Vaishampayan UN, Fontana J, Heilbrun LK, Smith D, Heath E, Dickow B, Figg WD.

Urol Oncol. 2014 Jan;32(1):31.e25-33. doi: 10.1016/j.urolonc.2012.11.017. Epub 2013 Feb 21.

17.

Phase II Study of Gemcitabine and Docetaxel Combination in Patients with Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.

Kafri Z, Heilbrun LK, Sukari A, Yoo G, Jacobs J, Lin HS, Mulrenan H, Smith D, Kucuk O.

ISRN Oncol. 2012;2012:159568. doi: 10.5402/2012/159568. Epub 2012 May 10.

18.

Percutaneous cryoablation of metastatic lesions from non-small-cell lung carcinoma: initial survival, local control, and cost observations.

Bang HJ, Littrup PJ, Currier BP, Goodrich DJ, Aoun HD, Klein LC, Kuo JC, Heilbrun LK, Gadgeel S, Goodman AC.

J Vasc Interv Radiol. 2012 Jun;23(6):761-9. doi: 10.1016/j.jvir.2012.02.013.

19.

Percutaneous cryoablation of metastatic renal cell carcinoma for local tumor control: feasibility, outcomes, and estimated cost-effectiveness for palliation.

Bang HJ, Littrup PJ, Goodrich DJ, Currier BP, Aoun HD, Heilbrun LK, Vaishampayan U, Adam B, Goodman AC.

J Vasc Interv Radiol. 2012 Jun;23(6):770-7. doi: 10.1016/j.jvir.2012.03.002. Epub 2012 Apr 25.

20.

Percutaneous Cryoablation of Metastatic Lesions from Colorectal Cancer: Efficacy and Feasibility with Survival and Cost-Effectiveness Observations.

Bang HJ, Littrup PJ, Currier BP, Goodrich DJ, Choi M, Heilbrun LK, Goodman AC.

ISRN Minim Invasive Surg. 2012;2012. pii: 942364.

21.

Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunction.

Gupta S, Parsa V, Heilbrun LK, Smith DW, Dickow B, Heath E, Vaishampayan U.

Anticancer Drugs. 2011 Sep;22(8):794-800. doi: 10.1097/CAD.0b013e328346af0d.

22.

Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer.

Naing A, Kurzrock R, Burger A, Gupta S, Lei X, Busaidy N, Hong D, Chen HX, Doyle LA, Heilbrun LK, Rohren E, Ng C, Chandhasin C, LoRusso P.

Clin Cancer Res. 2011 Sep 15;17(18):6052-60. doi: 10.1158/1078-0432.CCR-10-2979. Epub 2011 Jul 12.

23.
24.

Participation and survival of geriatric patients in Phase I clinical trials: the Karmanos Cancer Institute (KCI) experience.

Zafar SF, Heilbrun LK, Vishnu P, Jasti P, Venkatramanamoorthy R, Ding L, Lorusso PM, Heath EI.

J Geriatr Oncol. 2011 Jan 1;2(1):18-24.

25.

Recent epidemiology of Clostridium difficile infection during hematopoietic stem cell transplantation.

Chopra T, Chandrasekar P, Salimnia H, Heilbrun LK, Smith D, Alangaden GJ.

Clin Transplant. 2011 Jan-Feb;25(1):E82-7. doi: 10.1111/j.1399-0012.2010.01331.x. Epub 2010 Oct 25.

26.

A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3'- Diindolylmethane) in castrate-resistant, non-metastatic prostate cancer.

Heath EI, Heilbrun LK, Li J, Vaishampayan U, Harper F, Pemberton P, Sarkar FH.

Am J Transl Res. 2010 Jul 23;2(4):402-11.

27.

CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy.

Hammad N, Heilbrun LK, Philip PA, Shields AF, Zalupski MM, Venkatramanamoorthy R, El-Rayes BF.

Asia Pac J Clin Oncol. 2010 Jun;6(2):98-105. doi: 10.1111/j.1743-7563.2010.01290.x.

28.

Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin.

Vaishampayan UN, Burger AM, Sausville EA, Heilbrun LK, Li J, Horiba MN, Egorin MJ, Ivy P, Pacey S, Lorusso PM.

Clin Cancer Res. 2010 Jul 15;16(14):3795-804. doi: 10.1158/1078-0432.CCR-10-0503. Epub 2010 Jun 4.

29.

Squamous cell cancer of the anal canal in HIV-infected patients receiving highly active antiretroviral therapy: a single institution experience.

Hammad N, Heilbrun LK, Gupta S, Tageja N, Philip PA, Shields AF, Smith D, El-Rayes BF.

Am J Clin Oncol. 2011 Apr;34(2):135-9. doi: 10.1097/COC.0b013e3181dbb710.

30.

Impact of race, age, and socioeconomic status on participation in pancreatic cancer clinical trials.

El-Rayes BF, Jasti P, Severson RK, Almhanna K, Philip PA, Shields A, Zalupski M, Heilbrun LK.

Pancreas. 2010 Oct;39(7):967-71. doi: 10.1097/MPA.0b013e3181da91dd.

PMID:
20467351
31.
32.

A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers.

El-Rayes BF, Zalupski M, Bekai-Saab T, Heilbrun LK, Hammad N, Patel B, Urba S, Shields AF, Vaishampayan U, Dawson S, Almhanna K, Smith D, Philip PA.

Ann Oncol. 2010 Oct;21(10):1999-2004. doi: 10.1093/annonc/mdq065. Epub 2010 Mar 23.

33.

Sinonasal mucosal melanoma: a 13-year experience at a single institution.

Narasimhan K, Kucuk O, Lin HS, Heilbrun LK, Carron M, Venkatramanamoorthy R, Mathog R.

Skull Base. 2009 Jul;19(4):255-62. doi: 10.1055/s-0028-1115321.

34.

Clinicopathological analysis of primary epithelial appendiceal neoplasms.

Gupta S, Parsa V, Adsay V, Heilbrun LK, Smith D, Shields AF, Weaver D, Philip PA, El-Rayes BF.

Med Oncol. 2010 Dec;27(4):1073-8. doi: 10.1007/s12032-009-9337-2. Epub 2009 Oct 23.

35.

Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer.

Choi M, Heilbrun LK, Venkatramanamoorthy R, Lawhorn-Crews JM, Zalupski MM, Shields AF.

Am J Clin Oncol. 2010 Jun;33(3):257-61. doi: 10.1097/COC.0b013e3181a76a0b.

36.

Obesity is associated with atypia in breast ductal lavage of women with proliferative breast disease.

Djuric Z, Edwards A, Madan S, Darga L, Ren J, Blake C, Koletsky M, Heilbrun LK.

Cancer Epidemiol. 2009 Oct;33(3-4):242-8. doi: 10.1016/j.canep.2009.07.003. Epub 2009 Jul 28.

37.

A pilot trial of spirituality counseling for weight loss maintenance in African American breast cancer survivors.

Djuric Z, Mirasolo J, Kimbrough L, Brown DR, Heilbrun LK, Canar L, Venkatranamamoorthy R, Simon MS.

J Natl Med Assoc. 2009 Jun;101(6):552-64.

38.

Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer.

Vaishampayan UN, Marur S, Heilbrun LK, Cher ML, Dickow B, Smith DW, Al Hasan SA, Eliason J.

J Urol. 2009 Jul;182(1):317-23. doi: 10.1016/j.juro.2009.02.105. Epub 2009 May 17.

39.

Theoretical and practical application of traditional and accelerated titration Phase I clinical trial designs: the Wayne State University experience.

Heath EI, LoRusso PM, Ivy SP, Rubinstein L, Christian MC, Heilbrun LK.

J Biopharm Stat. 2009;19(3):414-23. doi: 10.1080/10543400902800460.

40.

Protein kinases C isozymes are differentially expressed in human breast carcinomas.

Ali S, Al-Sukhun S, El-Rayes BF, Sarkar FH, Heilbrun LK, Philip PA.

Life Sci. 2009 May 22;84(21-22):766-71. doi: 10.1016/j.lfs.2009.03.007. Epub 2009 Mar 24.

41.

Safety and Feasibility of Carboplatin and Paclitaxel followed by Fluoropyrimidine Analogs and Radiation as Adjuvant Therapy for Gastric Cancer.

Mobayed M, Heilbrun LK, Shields AF, Washington T, Venkatramanamoorthy R, Philip PA, El-Rayes BF.

Case Rep Oncol. 2009 Nov 21;2(3):220-228.

42.

Design of a Mediterranean exchange list diet implemented by telephone counseling.

Djuric Z, Vanloon G, Radakovich K, Dilaura NM, Heilbrun LK, Sen A.

J Am Diet Assoc. 2008 Dec;108(12):2059-65. doi: 10.1016/j.jada.2008.09.006.

43.

Phase II study of docetaxel and celecoxib, a cyclooxygenase-2 inhibitor, in elderly or poor performance status (PS2) patients with advanced non-small cell lung cancer.

Gadgeel SM, Wozniak A, Ruckdeschel JC, Heilbrun LK, Venkatramanamoorthy R, Chaplen RA, Kraut MJ, Kalemkerian GP.

J Thorac Oncol. 2008 Nov;3(11):1293-300. doi: 10.1097/JTO.0b013e31818b194e.

44.

Phase II trial of capecitabine and weekly docetaxel in metastatic renal cell carcinoma.

Marur S, Eliason J, Heilbrun LK, Dickow B, Smith DW, Baranowski K, Alhasan S, Vaishampayan U.

Urology. 2008 Oct;72(4):898-902. doi: 10.1016/j.urology.2008.05.032. Epub 2008 Aug 9.

45.

Analysis and reproducibility of 3'-Deoxy-3'-[18F]fluorothymidine positron emission tomography imaging in patients with non-small cell lung cancer.

Shields AF, Lawhorn-Crews JM, Briston DA, Zalzala S, Gadgeel S, Douglas KA, Mangner TJ, Heilbrun LK, Muzik O.

Clin Cancer Res. 2008 Jul 15;14(14):4463-8. doi: 10.1158/1078-0432.CCR-07-5243.

46.

Retrospective review of cancer patients > or =80 years old treated with chemotherapy at a comprehensive cancer center.

Choi M, Jiang PQ, Heilbrun LK, Smith DW, Gadgeel SM.

Crit Rev Oncol Hematol. 2008 Sep;67(3):268-72. doi: 10.1016/j.critrevonc.2008.04.006. Epub 2008 Jul 2.

47.

Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers.

Morris R, Alvarez RD, Andrews S, Malone J, Bryant C, Heilbrun LK, Smith D, Schimp V, Munkarah A.

Gynecol Oncol. 2008 Jun;109(3):346-52. doi: 10.1016/j.ygyno.2008.02.028. Epub 2008 Apr 14.

48.

Exfoliated cells in stool: a source for reverse transcription-PCR-based analysis of biomarkers of gastrointestinal cancer.

Yu YJ, Majumdar AP, Nechvatal JM, Ram JL, Basson MD, Heilbrun LK, Kato I.

Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):455-8. doi: 10.1158/1055-9965.EPI-07-2515.

49.

Phase II trial of pegylated interferon and thalidomide in malignant metastatic melanoma.

Vaishampayan UN, Heilbrun LK, Marsack C, Smith DW, Flaherty LE.

Anticancer Drugs. 2007 Nov;18(10):1221-6.

PMID:
17893524
50.

Tumor imaging using 1-(2'-deoxy-2'-18F-fluoro-beta-D-arabinofuranosyl)thymine and PET.

Tehrani OS, Muzik O, Heilbrun LK, Douglas KA, Lawhorn-Crews JM, Sun H, Mangner TJ, Shields AF.

J Nucl Med. 2007 Sep;48(9):1436-41.

Supplemental Content

Loading ...
Support Center